Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology)
Source: Diabetes Technology - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology and Therapeutics)
Source: Diabetes Technology and Therapeutics - January 27, 2020 Category: Endocrinology Authors: James Thrasher Sarit Polsky Lionel Hovsepian Irene Nowotny Suzanne Pierre B éatrice Bois De Fer Anuj Bhargava Bhaswati Mukherjee Satish K. Garg Source Type: research

Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Date: May 6, 2019 Issue #:  1571Summary:  View the Expanded Table: Some Available Insulins (Source: The Medical Letter)
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research

Insulins for Type 2 Diabetes
Date: May 6, 2019 Issue #:  1571Summary:  The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is
Source: The Medical Letter - April 3, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Detemir Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research

Fiasp - Another Insulin Aspart Formulation for Diabetes
Date: January 1, 2018 Issue #:  1537Summary:  The FDA has approvedFiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes.Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart(Novolog). (Source: The Medical Letter)
Source: The Medical Letter - November 29, 2017 Category: Drugs & Pharmacology Authors: admin Source Type: research

Pre-Clinical in Vitro and in Vivo Evidence for Plausible Mechanisms Underlying the Risk of Cancer Associated with Insulin and Insulin Analogues.
Conclusion: In general many studies on pre-clinical in vitro and in vivo evidence for plausible mechanisms underlying the risk of cancer associated with insulin and insulin analogues exist. However, the level of evidence or a causal association between insulin and insulin analogues and cancer is low. PMID: 24215309 [PubMed - as supplied by publisher] (Source: Current Drug Safety)
Source: Current Drug Safety - November 7, 2013 Category: Drugs & Pharmacology Authors: Vestergaard P, Starup-Linde J Tags: Curr Drug Saf Source Type: research

Mylan, Biocon in deal on insulin products
Mylan and Biocon Ltd. are in a partnership to develop and commercialize three generic insulin analog products. Financial terms of the profit-sharing deal weren't disclosed. But Mylan will be able to develop Glargine, the generic version of Sanofi's Lantus; Lispro, the generic version of Eli Lilly's Humalog; and Aspart, the generic version of Nov Nordisk's NovoLog. The rights are for the U.S., Canada, the European Union and elsewhere. The worldwide sales of the three are $11.5 billion in 2012, Mylan… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 14, 2013 Category: Pharmaceuticals Source Type: research